FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status

Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of BRCA mutational status